Home Featured Page 20

Featured

Latest

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

High Hopes in the Mile High City: Inside Colorado’s First Licensed Psilocybin Center

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Oakland Psychedelic Conference

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

Psychedelic Research: The Current Landscape and Future Directions

Understanding Bad Trips: The Power and Potential of Adverse Psychedelic Experiences

Pα+ Psychedelic Bulletin #168:

Ecopsychology, Plant Dietas, and Plant Consciousness: Building a Relationship with Nature

Women’s Health and Psychedelics – New Insights

Regenerative Business in Psychedelics: A Sustainable Path Forward

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

1...192021...285 Page 20 of 285

EDITOR PICKS

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

High Hopes in the Mile High City: Inside Colorado’s First Licensed Psilocybin Center

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Psychedelic Science 2025

Oakland Psychedelic Conference

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

Psychedelic Research: The Current Landscape and Future Directions

Understanding Bad Trips: The Power and Potential of Adverse Psychedelic Experiences

Pα+ Psychedelic Bulletin #168:

Ecopsychology, Plant Dietas, and Plant Consciousness: Building a Relationship with Nature

Women’s Health and Psychedelics – New Insights

Regenerative Business in Psychedelics: A Sustainable Path Forward

Meditation, Exploring Spiritual Traditions, and the Wisdom of Plant Medicine

EDITOR PICKS

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY